vs
Side-by-side financial comparison of IMAX CORP (IMAX) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $125.2M, roughly 1.6× IMAX CORP). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $28.0M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 8.5%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IMAX vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $196.9M |
| Net Profit | $637.0K | — |
| Gross Margin | 57.6% | 79.5% |
| Operating Margin | 19.3% | 1.2% |
| Net Margin | 0.5% | — |
| Revenue YoY | 35.1% | 5.1% |
| Net Profit YoY | -88.0% | — |
| EPS (diluted) | $0.02 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $196.9M | ||
| Q3 25 | $106.7M | $179.5M | ||
| Q2 25 | $91.7M | $181.1M | ||
| Q1 25 | $86.7M | $168.9M | ||
| Q4 24 | $92.7M | $187.3M | ||
| Q3 24 | $91.5M | $168.6M | ||
| Q2 24 | $89.0M | $178.0M | ||
| Q1 24 | $79.1M | $167.1M |
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $5.4M | ||
| Q2 25 | $11.3M | $-4.8M | ||
| Q1 25 | $2.3M | $4.8M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $-143.5M | ||
| Q2 24 | $3.6M | $18.9M | ||
| Q1 24 | $3.3M | $9.0M |
| Q4 25 | 57.6% | 79.5% | ||
| Q3 25 | 63.1% | 80.9% | ||
| Q2 25 | 58.5% | 77.4% | ||
| Q1 25 | 61.4% | 79.7% | ||
| Q4 24 | 52.2% | 78.7% | ||
| Q3 24 | 55.8% | 76.9% | ||
| Q2 24 | 49.4% | 75.1% | ||
| Q1 24 | 59.3% | 71.6% |
| Q4 25 | 19.3% | 1.2% | ||
| Q3 25 | 27.2% | 3.5% | ||
| Q2 25 | 15.6% | 4.7% | ||
| Q1 25 | 19.3% | 1.2% | ||
| Q4 24 | 10.3% | 13.2% | ||
| Q3 24 | 21.2% | -82.8% | ||
| Q2 24 | 3.2% | 15.9% | ||
| Q1 24 | 15.3% | 7.9% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | 3.0% | ||
| Q2 25 | 12.3% | -2.7% | ||
| Q1 25 | 2.7% | 2.8% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | -85.1% | ||
| Q2 24 | 4.0% | 10.6% | ||
| Q1 24 | 4.1% | 5.4% |
| Q4 25 | $0.02 | $0.05 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.20 | $-0.11 | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $0.09 | $0.38 | ||
| Q3 24 | $0.26 | $-3.11 | ||
| Q2 24 | $0.07 | $0.39 | ||
| Q1 24 | $0.06 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $337.9M | $693.1M |
| Total Assets | $894.0M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $238.4M | ||
| Q3 25 | $143.1M | $246.3M | ||
| Q2 25 | $109.3M | $445.9M | ||
| Q1 25 | $97.1M | $493.6M | ||
| Q4 24 | $100.6M | $484.6M | ||
| Q3 24 | $104.5M | $453.8M | ||
| Q2 24 | $91.6M | $404.2M | ||
| Q1 24 | $81.0M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $337.9M | $693.1M | ||
| Q3 25 | $349.5M | $727.2M | ||
| Q2 25 | $320.4M | $757.8M | ||
| Q1 25 | $299.5M | $798.5M | ||
| Q4 24 | $299.5M | $778.3M | ||
| Q3 24 | $289.4M | $749.6M | ||
| Q2 24 | $267.2M | $879.3M | ||
| Q1 24 | $258.8M | $892.2M |
| Q4 25 | $894.0M | $1.3B | ||
| Q3 25 | $889.6M | $1.3B | ||
| Q2 25 | $868.6M | $1.5B | ||
| Q1 25 | $848.3M | $1.6B | ||
| Q4 24 | $830.4M | $1.6B | ||
| Q3 24 | $847.6M | $1.5B | ||
| Q2 24 | $827.4M | $1.6B | ||
| Q1 24 | $824.1M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $43.7M |
| Free Cash FlowOCF − Capex | $28.0M | $43.5M |
| FCF MarginFCF / Revenue | 22.3% | 22.1% |
| Capex IntensityCapex / Revenue | 1.1% | 0.1% |
| Cash ConversionOCF / Net Profit | 46.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $43.7M | ||
| Q3 25 | $67.5M | $60.8M | ||
| Q2 25 | $23.2M | $12.0M | ||
| Q1 25 | $7.0M | $35.5M | ||
| Q4 24 | $11.5M | $33.1M | ||
| Q3 24 | $35.3M | $53.9M | ||
| Q2 24 | $35.0M | $53.2M | ||
| Q1 24 | $-11.0M | $49.1M |
| Q4 25 | $28.0M | $43.5M | ||
| Q3 25 | $64.8M | $57.0M | ||
| Q2 25 | $20.9M | $9.3M | ||
| Q1 25 | $5.3M | $26.9M | ||
| Q4 24 | $6.9M | $31.0M | ||
| Q3 24 | $34.2M | $49.8M | ||
| Q2 24 | $33.5M | $51.6M | ||
| Q1 24 | $-12.1M | $46.3M |
| Q4 25 | 22.3% | 22.1% | ||
| Q3 25 | 60.7% | 31.7% | ||
| Q2 25 | 22.8% | 5.1% | ||
| Q1 25 | 6.1% | 15.9% | ||
| Q4 24 | 7.4% | 16.6% | ||
| Q3 24 | 37.3% | 29.6% | ||
| Q2 24 | 37.6% | 29.0% | ||
| Q1 24 | -15.3% | 27.7% |
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 2.6% | 2.2% | ||
| Q2 25 | 2.6% | 1.5% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | 5.0% | 1.1% | ||
| Q3 24 | 1.2% | 2.4% | ||
| Q2 24 | 1.8% | 0.9% | ||
| Q1 24 | 1.4% | 1.7% |
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | 11.20× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | 7.37× | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | 2.82× | ||
| Q1 24 | -3.35× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
